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Oral anticoagulantsAtrial ﬁbrillation is the most common cardiac arrhythmia in the general population, with a prevalence of 1–3%,
which increases with age, reaching 15% in elderly people. Prophylaxis of ischemic stroke with warfarin was the
gold standard ofmedicalmanagement formany years. On the otherhandheparin andwarfarinwas themainphar-
macologic agents for the prophylaxis/treatment of venous thromboembolism. In the last 5 yearswarfarin is getting
replaced by non-vitamin K antagonist oral anticoagulants at least partly. In this article it is attempted to foresee
whether new oral anticoagulants will become the new standard of care in anticoagulation therapy.
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In recent years, the development of novel oral anticoagulant agents
(NOACs) such as dabigatran, rivaroxaban, apixaban and edoxaban has
given health-care providers better treatment alternatives to aspirin,
clopidogrel, heparin and warfarin, mainly for stroke prophylaxis in
patients with non-valvular atrial ﬁbrillation (NVAF), for prophylaxis/
treatment of venous thromboembolism (VTE) and also for the second-
ary prophylaxis of acute coronary syndromes (ACS).1–3
Atrial ﬁbrillation (AF) is the most frequently encountered dysrhyth-
mia, which may lead to an increased risk of stroke. It may result in
signiﬁcant unfavorable health outcomes that include but are not limited
to a 5-fold increased risk of stroke, hospitalization, impaired quality of
life, and decreased work productivity. Stroke is a costly diseaseiversity Faculty of Medicine,
a, İzmir, Turkey. Tel.: +90 232
diovascular Academy.
y. Production and hosting by Elsevfrom the perspective of individual, family, and society. AF-related stroke
may lead to devastating consequences in terms of health andwell-being
of an individual. In patients with AF-related adverse events
(e.g., thromboembolic infarctions), the outcomes are often poor, and
may result in severe permanent neurologic deﬁcit or mortality.4–8
Venous thromboembolism is the thirdmost common cardiovascular
condition after ACS and stroke.9 Although the exact incidence of VTE
remains unknown, it is estimated that there are approximately 1million
cases in the United States per year, many of which represent recurrent
disease.10 Nearly two thirds of all VTE events result from hospitalization
and approximately 300,000 of these patients die.11 Pulmonary embo-
lism is the third most common cause of hospital-related death.12,13
The standard effective treatment of venous and arterial thromboem-
bolism includes the use of unfractionated and low-molecular weight
heparins as well as warfarin, which is associated with major disadvan-
tages. In recent years, new anticoagulants have been developed in an
attempt to overcome the known limitations of the established treat-
ment approach and to provide improved therapies for the affected
patients.14–17
A meta-analysis published in 2007, of all currently available
randomized trials that extend observations about the efﬁcacy and safetyier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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AF showed that compared with the control, adjusted-dose warfarin and
antiplatelet agents reduced stroke by 64% and 22% respectively.1 In
2013 a meta-analysis reported that new oral anticoagulants (NOACs)
signiﬁcantly reduced stroke or systemic embolic events by 19% com-
pared with warfarin. New oral anticoagulants also signiﬁcantly reduced
all-cause mortality compared with warfarin.2
NOACs can be divided into two broad classes: (i) Direct thrombin
inhibitors (dabigatran), which inhibit thrombin (Factor IIa), and (ii)
Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), which inhibit
factor Xa. Rivaroxaban, apixaban and edoxaban are oral, selective factor
Xa inhibitors which block the active site of factor Xa, and these agents
do not require a co-factor to exert their effects. The oral direct thrombin
inhibitor, dabigatran, prevents the formation of thrombin through inhi-
bition of the thrombin-dependent conversion of ﬁbrinogen to ﬁbrin.
Dabigatran, rivaroxaban, apixaban and edoxaban inhibit both free and
clot-bound ﬁbrin, and indirectly inhibit thrombin-induced platelet
aggregation.18,19
NOACs offer major pharmacological advantages over vitamin K
antagonists (e.g., warfarin), including rapid onset/offset of action, few
drug interactions, and predictable pharmacokinetics, which eliminates
the requirement for regular coagulation monitoring associated with
conventional anticoagulant therapy.18 From 2008, regulatory agencies
in EU and US have approved several NOACs for speciﬁc indications
based on the results obtained in clinical trials demonstrating efﬁcacy
and safety that are at least non-inferior, if not superior, compared to
warfarin (for stroke prevention in AF as well as for treatment and sec-
ondary prevention of venous thromboembolism) or the injectable
agent, low-molecular-weight heparin (Table 1).
The aim of this paper is to predict whether NOACs will become the
new standard of care for the treatment of patients with NVAF and
VTE. References are made to IMS (International Medical Statistics)
Healthcare data to understand the trends in the global anticoagulation
market.
Disclosure of global anticoagulant market sales was requested from
IMS to investigate the development of the global anticoagulant market
and to predict whether NOACs are likely to become the standard of
care in their approved indications such as stroke prevention in NVAF
and treatment of VTE. The claims in this paper are based on IMS Health
global anticoagulant market sales data from 2008 to 2014.
Discussion
The decline in stroke mortality over the past decades has resulted
from reduced stroke incidence and lower case fatality rates. The signif-
icant improvements in stroke outcomes are concurrent with cardiovas-
cular risk factor control interventions. US health statistics shows that
from 2001 to 2011, the relative rate of stroke death fell by 35% and the
actual number of stroke deaths declined by 21%.20 Stroke prevention
is central to the appropriate control of hypertension, diabetes, highTable 1
Approved NOAC's in EU and US.
http://ec.europa.eu/health/documents/community-register/html/alfregister.htm.
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
NOACs Prevention of venous thromboembolism in patients
undergoing hip/knee replacement surgery
Stroke prevention in
non-valvular atrial ﬁbr
US EU US EU
Dabigatran – Mar '08 Oct '10 Aug '
Rivaroxaban July '11 Sept '08 Nov '11 Dec '1
Apixaban March '14 May '11 Dec '12 Nov '
Edoxaban na⁎ na⁎ Jan '15 –
⁎ Only in Japan, not in EU/US.cholesterol, smoking cessation and management of atrial ﬁbrillation.
Until recently, the focus was to identify high-risk patients who would
be givenwarfarin.Warfarinworks bestwith high-quality anticoagulation
(INR adjusted) control. High times in therapeutic range (N70%) are asso-
ciatedwith the best efﬁcacy and safety of vitamin K antagonists, with low
rates of stroke and bleeding.
Previously the only available anticoagulant was a vitamin K antago-
nist, but clinicians now have a choice and can ﬁt the drug to the patient,
and vice versa. In the last 5 years management of stroke prevention has
changed with the availability of NOAC's. Thus, contemporary guidelines
have focused on the initial identiﬁcation of low-risk patients. Several
NOACs now exist, offering similar (or better) effectiveness, safety, and
convenience to the vitamin K antagonists. Dabigatran, rivaroxaban,
apixaban and edoxaban is highly effective in reducing the risk of
thromboembolic stroke with a more favorable safety proﬁle. Although
the bleeding risk is not negligible with NOAC's it is much better than
anticoagulation with INR adjusted warfarin. NOACs have been released
to the market in 2008, and the question of whether these agents will
replace warfarin and heparins, which have been accepted as the
gold standard for many years, is one that needs to be answered
after a thorough evaluation of several aspects. Will NOACs continue
their upward trend and replace warfarin as the standard of care in
upcoming years?
In order to answer this question, the present paper will seek the
answers to the following:
1. Are the newagents used in all indications forwhich standard therapy
with warfarin and heparin can be used?
2. What are the beneﬁts of NOACs over standard treatment in indica-
tions approved by the authorities?
3. To what extent are the physicians aware of these beneﬁts and how
much do they adapt to these advantages?
4. Are the new agents superior to standard therapy in terms of
treatment costs?
5. Starting from the release of the new agents in the market, how has
the dynamics changed for the global anticoagulant market?
Will NOACs continue their upward trend and replacewarfarin as the
standard of care in upcoming years
1. All of the pivotal trials comparing VKAs with NOACs in AF have
enrolled patients with so-called NVAF, and excluded patients at
particularly high risk of thromboembolism, such as thosewith AF ac-
companied bymitral stenosis or patients with mechanical prosthetic
valves. The reasons for excluding these patients in trials evaluating
NOACs included the possibility that the pathogenesis of thromboem-
bolismmay be substantially different from other types of AF.21 In this
context, it is not possible to use NOACs in patients with valve related
conditions in light of the available data.illation
Treatment/secondary prophylaxis of deep
vein thrombosis and pulmonary embolism
Secondary prevention of acute
coronary syndromes
US EU US EU
11 June '14 April '14 – –
1 Nov '12 Dec '11 (DVT)
Nov'12 (PE)
– May '13
12 July '14 Aug '14 – –
Jan '15 – – –
Fig. 1. Global AC Market Volume Shares in % (based on DoT*). Source: IMS MIDAS, Data-
base: Current All 2014. *DoT = days of therapy, calculated based on volume in SU (stan-
dard units). For dabigatran and apixaban: DOT = SU divided by 2 (assumption: two
tablets per day). For VKA, rivaroxaban: DOT = SU (assumption: 1 tablet per day).
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in patients with NVAF have shown non-inferiority compared to
Vitamin K antagonists.22–24 All new generation oral anticoagulants
have signiﬁcantly decreased the risk of hemorrhagic stroke and in-
tracranial bleeding, and they have not been associated with an
apparent increase in major bleeding risk compared to warfarin.22–24
Consistent with the ﬁndings of the major studies, results of meta-
analysis have demonstrated signiﬁcantly decreased rates of stroke
or systemic embolism andhemorrhagic strokewith these treatments
compared to warfarin.25 However, because of the heterogeneity of
different studies and the lack of head-to-head clinical trials with
NOACs, one cannot draw a conclusion to say which of these agents
is the best option.26
3. While it is not possible to exactly know to what extent physicians
adopt the superiority that NOACs demonstrate in different therapeu-
tic ﬁelds, investigating NOAC usage data in different countries may
be informative. In this regard, market data may reﬂect that these
agents are adopted at different levels in different parts of the
world. Looking at the number of tablets patients use (standard
units), it can be concluded that: While the use of NOACs is approxi-
mately 35% of that of the agents accepted as standard (warfarin +
heparin) in US, it is around 15% in “Emerging Markets” region,
which also includes Turkey.27
4. Stroke leads to substantialﬁnancial burden on healthcare systems, as
well as on patients, family, and society. The lifetime cost of an ische-
mic strokewas estimated to be over $90,000 for an individual patient
in 1990, and the American Heart Association estimated that the total
national cost (direct plus indirect costs) of stroke in the United States
exceeded $34 billion in 2008.28,29
Treatment cost often poses a concernwithNOACs.However, the total
exact cost of strokes and the provision of anticoagulationmonitoring
is not completely understood and considered when assessing
the cost impact of NOACs. Costs incurred by patient visits to
anticoagulation monitoring clinics, and the cost of hospital admis-
sions and other factors of managing the adverse effects of warfarin,
are not always taken into account.
In 2013, Harrington et al. conducted a cost effectiveness study taking
into consideration the aforementioned factors. Their study compared
the cost effectiveness of warfarin to that of dabigatran, rivaroxaban
and apixaban, which had been approved by authorities as of 2013.
The modeled population in this study was a hypothetical cohort of
70-year old patients with NVAF, increased risk for stroke
(CHADS2 ≥ 1), renal creatinine clearance ≥50 mL/min, and no previ-
ous contraindications to anticoagulation. The study ﬁndings demon-
strated that all of the new generation agents were cost-effective
compared to warfarin.30
It may be predicted that growing data from such studies may re-
sult in positive contributions in favor of NOACs from the policy
maker perspective; and in this regard, one may suggest that
NOACs are candidates to replace warfarin in anticoagulation
therapy.
5. When answering the question of whether NOACsmay ormay not re-
place the widely accepted gold standard therapy with warfarin and
heparin for their respective indications in certain therapeutic ﬁelds,
one should also consider how the dynamics of the market have
changed since the introduction of NOACs in 2008 to date.
As per the IMS data regarding the global anticoagulant market,
warfarin use has declined from 87,5% to 72% through 2008 to 2014. In
contrast, NOACs have reached a market share of 15,5% as of 2014
(Fig. 1).
Fig. 1 presents the standard units (number of tablets the patients
receive) data of 2014 showing a 1.35-fold higher usage rate for Factor
Xa inhibitors compared to direct thrombin inhibitors. Standard units
show that rivaroxaban as the most commonly preferred agent among
Factor Xa inhibitors as of 2014.Conclusion
The success of theseNOACdrugsmeans thatwarfarinwill eventually
become redundant in patients with NVAF, VTE and pulmonary embo-
lism. This might take several years. In stroke prevention, these drugs
are major breakthrough and stroke prevention is muchmore important
than which drug is better than the others. That is a question hard to an-
swer and at the moment is based more on opinions than fact.Disclosure statement
The authors have no ﬁnancial support or conﬂicts of interest to
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